Commission Implementing Regulation (EU) 2023/1079 of 2 June 2023 approving (13Z)-hexadec-13-en-11-yn-1-yl acetate as an active substance for use in biocidal products of product-type 19 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2023/1079
• Articles: 3

Article 1

(13 Z )-hexadec-13-en-11-yn-1-yl acetate is approved as an active substance for use in biocidal products of product-type 19 subject to the conditions set out in the Annex.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

Common Name

IUPAC Name

Identification Numbers

Minimum degree of purity of the active substance  ( 1 )

Date of approval

Expiry date of approval

Product type

Specific conditions

(13 Z )-Hexadec-13-en-11-yn-1-yl acetate

IUPAC name: (13 Z )-hexadec-13-en-11-yn-1-yl acetate

EC No: Not allocated

CAS No: 78617-58-0

970 g/kg dry weight

1 June 2023

31 May 2033

19

The authorisation of biocidal products is subject to the following conditions:

The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any of the uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. For uses leading to higher exposure of the users, by-standers or the environment compared to the Union level risk assessment of the active substance, applications for product authorisation shall contain all data required for active substances in accordance with Annex II to Regulation (EU) No 528/2012, subject to the possibilities of adaptation of the data requirements in accordance with Annex IV to that Regulation.

( 1 )   The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.